Effect of Intermittent Hypoxia on Ventilatory Endurance in Healthy Volunteers

NCT ID: NCT06714435

Last Updated: 2025-11-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-16

Study Completion Date

2025-10-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sleep apnoea syndrome is a common disorder responsible for poor sleep quality and repeated oxygen depletion in the blood. Patients suffering from this disease experience a reduction in their endurance, i.e. their ability to make prolonged efforts. This loss of muscular endurance affects breathing in particular. It is known that poor sleep reduces endurance, but it is not knwon whether the repeated lack of oxygen for several hours at night also has this effect. This information could help improve the management of certain acute respiratory illnesses (asthma attacks, respiratory infections, etc.).

This project therefore seeks to establish a link between repeated oxygen deprivation and a reduction in the human brain's ability to train respiratory muscles. To this end, the healthy volunteers in this study will perform the same breathing exercise (breathing for as long as possible through a mask that makes inspiration difficult) twice: once after 6 hours' exposure to repeated oxygen deprivation, and once under conditions of normal oxygenation. The order of these exercises will be randomized. These exercises will take place in a special room, a hypoxia chamber, where it is possible to deplete the air breathed in oxygen.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intermittent Hypoxia Respiratory Endurance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Groupe 1

Control visit in normoxia at V1 and then test visit in intermittent hypoxia at V2

Group Type EXPERIMENTAL

Intermittent hypoxia

Intervention Type OTHER

Intermittent hypoxia during 6 hours in daytime

Normoxia

Intervention Type OTHER

Normoxia during 6 hours in daytime

Groupe 2

Test visit in intermittent hypoxia at V1 and then control visit in normoxia at V2

Group Type EXPERIMENTAL

Intermittent hypoxia

Intervention Type OTHER

Intermittent hypoxia during 6 hours in daytime

Normoxia

Intervention Type OTHER

Normoxia during 6 hours in daytime

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intermittent hypoxia

Intermittent hypoxia during 6 hours in daytime

Intervention Type OTHER

Normoxia

Normoxia during 6 hours in daytime

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-excessive coffee drinker (\< 3 espressos / day)
* Non-smoker or weaned for 3 months and total consumption \< 10 packs/year
* With a BMI within \]18 - 25\[ kg/m².
* Benefiting from a Social Security plan or benefiting from one through a third party
* Giving free, informed and signed consent, after receiving clear and fair information about the study.


* History of respiratory or ENT disease (asthma, chronic bronchitis, COPD, respiratory allergy, swallowing disorders, oropharyngeal malformation, obstructive or central sleep apnea-hypopnea syndrome, alveolar hypoventilation syndrome)
* Respiratory, cardiovascular, muscular, neurological or diabetic pathology or disorders
* Raynaud's disease/syndrome
* History of epilepsy or history of malaise suggestive of epilepsy
* Psychiatric history requiring hospitalization
* Liver failure
* Renal insufficiency
* History of acute mountain sickness (presence during or after a stay at altitude of symptoms of vertigo, headache, nausea/vomiting and incapacitating fatigue: Lake Louise score \> 0)
* History of migraines
* Taking medications that interfere with respiratory function or cardiovascular function, or psychotropic drugs ( anxiolytic, sedative, antidepressant, neuroleptic, muscle relaxant, etc.).
* Alcohol or drug dependence
* Anemia, sickle-cell anemia
* SpO2 \< 97% at rest in room air
* Currently participating in another clinical study
* Protected persons within the meaning of article L1121-5 to 8 (persons benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, pregnant or breast-feeding women, persons staying in a health or social establishment, adults under legal protection, and patients in emergency situations). - Women with childbearing capacity who do not have effective contraception (hormonal/mechanical: oral, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy).
* Incidental finding of acute mountain sickness (Lake Louise score \>0)
* Pregnant woman (incidental finding)
* Persistence of average sleep time \< 6h
* Non-reversible deterioration in volunteer's state of health within study period
* Electroencephalogram signal unusable
Minimum Eligible Age

25 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Poitiers University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Céline ABONNEAU

Role: STUDY_CHAIR

CHU Poitiers

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Poitiers

Poitiers, France, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ENDUR-HYPOX

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.